Wenbo Guo

机构：Sun Yat-sen University, The First Affiliated Hospital, Sun Yat-sen University · ORCID：0000-0002-1017-4640

发表论文 37 篇 · 总被引 437 次 · h-index 11

代表论文

• Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study (2021 · Journal of Cancer Research and Clinical Oncology · 被引 114)
• Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study (2021 · BMC Cancer · 被引 67)
• Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib and Tislelizumab with or Without Transhepatic Arterial Embolization for Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombus and High Tumor Burden: A Multicenter Retrospective Study (2023 · Journal of Hepatocellular Carcinoma · 被引 24)
• Estimating tumor mutational burden across multiple cancer types using whole-exome sequencing (2021 · Annals of Translational Medicine · 被引 21)
• HAIC plus lenvatinib and tislelizumab for advanced hepatocellular carcinoma with Vp4 portal vein invasion (2025 · Hepatology International · 被引 19)
• Efficacy and safety of transcatheter arterial chemoembolization plus hepatic arterial infusion chemotherapy in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis in the main trunk (2022 · Journal of Cancer Research and Therapeutics · 被引 16)